NACDS insists that comprehensive DIR fee reform now depends on further legislative and regulatory action to improve predictability, fairness, and viability for pharmacies.
Darren Herring (left), district director for U.S. Rep. Trent Kelly (R-MS), participated in a Kroger pharmacy tour in Tupelo, MS, where he met with Kroger pharmacy team member Greg Wood (right). To engage your company in the NACDS RxIMPACT Pharmacy Tour Program, please contact Heidi Ecker at Hecker@nacds.org. | Photo Credit: Kroger
Groups applaud CMS’ ongoing efforts to address DIR fees; urge further action for comprehensive pharmacy DIR reform that “reduce[s] [Medicare] beneficiary drug costs and also protect[s] pharmacy access”.
NACDS comment letter to Biden Administration urges CMS to finalize proposal, implement regulatory guardrails and standardized pharmacy measures that best serve Medicare patients and help protect pharmacy viability.
NACDS to prepare recommendations to maximize this historic opportunity to reduce seniors’ out-of-pocket drug costs and to help preserve critical, convenient and equitable pharmacy access.
NACDS today said that omitting pharmacy direct and indirect remuneration (DIR) fee reforms from the Build Back Better Act budget reconciliation bill will deprive Medicare beneficiaries of between $7.1 and $9.2 billion over 10 years in reduced cost-sharing for prescription drugs, according to Centers for Medicare and Medicaid Services (CMS) estimates.
249 organizations sign letter urging Congress to reduce senior drug costs by addressing backdoor pharmacy price concessions.
Direct and indirect remuneration (DIR) fees continue to rise at an alarming rate, inflating seniors’ out-of-pocket prescription drug costs and jeopardizing the viability of pharmacies and patient access.
Urges Congress to pass legislation to reduce patients’ out-of-pocket costs and to prevent pharmacy closures jeopardizing patient access.
As the House Committee on Energy and Commerce’s Health Subcommittee pursues drug-pricing reform, NACDS also pledges to work with Congress for policies that would not further undermine or complicate pharmacy reimbursement in the Part D program nor potentially harm patients’ access to affordable care
